Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
18.46
+0.09 (+0.49%)
Official Closing Price
Updated: 7:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
↗
October 20, 2021
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Bitcoin Futures Arrive
↗
October 19, 2021
Today you can finally hold Bitcoins via an exchange-traded fund.
Via
Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
↗
October 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...
Via
Benzinga
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
↗
October 19, 2021
Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue...
Via
Benzinga
Calithera Buys Two Oncology Candidates From Takeda For $45M
↗
October 19, 2021
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK)....
Via
Benzinga
Chinese Growth Level
↗
October 18, 2021
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.
Via
Talk Markets
Europe's Unicorns
↗
October 15, 2021
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.
Via
Talk Markets
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
↗
October 15, 2021
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
↗
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
↗
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Perfumes Of Arabia
↗
October 06, 2021
Downtrends do eventually run out of pessimistic steam, but it can take a while.
Via
Talk Markets
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
↗
October 06, 2021
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 06, 2021
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a...
Via
Benzinga
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
↗
October 06, 2021
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the...
Via
Benzinga
Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests
↗
October 06, 2021
Takeda Pharmaceutical was testing a drug called TAK-994 in narcolepsy patients.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 06, 2021
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9...
Via
Benzinga
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
↗
October 06, 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin...
Via
Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
↗
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding...
Via
Talk Markets
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
↗
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
↗
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
↗
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
↗
October 01, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA...
Via
Benzinga
September Ends
↗
September 30, 2021
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling.
Via
Talk Markets
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
↗
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Takeda In-Licenses Hunter Syndrome Candidate
↗
September 30, 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to...
Via
Benzinga
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
↗
September 24, 2021
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in...
Via
Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
↗
September 21, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
↗
September 21, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...
Via
Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
↗
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
↗
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.